Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Monitoring microRNAs
June 2018
SHARING OPTIONS:

BOULDER, Colo.—Clinical-stage biopharmaceutical company miRagen Therapeutics Inc. presented data at the recent 2018 Association for Research in Vision and Ophthalmology Annual Meeting from two new preclinical studies. The studies in question are focused on microRNA mimics of the microRNA-183/96/182 cluster and MRG-201, a microRNA-29 mimic, as potential treatments for ophthalmic diseases. Work with microRNAs of the microRNA-183/96/182 cluster found that microRNA modulators can be functionally delivered to the eye in animal models. The studies also found that these mimics could engender functional improvement of photoreceptors and vision in a mouse model of retinal degeneration. MRG-201 was found to be readily taken up into the cornea and all retinal layers after intravitreal injection, and also led to reduced expression of collagens and microRNA-29 target genes that play a role in fibrogenesis.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.